Aussie HIV/AIDS Groups Protest Coverage Delays For Hepatitis B Tests
This article was originally published in PharmAsia News
Executive Summary
HIV/AIDS groups in Australia accuse the federal government of unnecessarily delaying for at least six years approval of coverage for a diagnostic for hepatitis B. The government relies on its Medical Services Advisory Committee to recommend federal funding for medical procedures based on their safety and effectiveness. Recently the HIV/AIDS and other groups have complained about the panel's lack of accountability for its approvals process. The HIV/AIDS groups noted it took three years to approve a procedure for determining a patient's hepatitis B viral load because the panel lost paperwork. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.